Skip to main content
OpenTrials
Completed

NCT Number: NCT04083560

A Comparison of Two Different Doses of Maternal B12 Supplementation in Improving Infant B12 Deficiency and Neurodevelopment

Supplementation with Iron and folate have been part of a worldwide strategy targeting anaemia and neural tube defects for many years. However, vitamin B12 deficiency has received much less attention. High prevalence of deficiency in mothers in the antenatal period and in their infants, has been documented. Multiple case series document the neurological consequences of severe deficiency and their reversal with B-12. Trials on the subject are limited and those available have either used an ineffective dose or for a short duration.

Therefore, we propose this randomised controlled trial to compare the efficacy of two different doses (pharmacological and preventive) of maternal Vitamin B-12 supplementation in improving infant B12 deficiency and neurodevelopment. We propose to undertake a multi-centric trial in India and Nepal given the high prevalence of deficiency reported from these countries and to allow a wider socio-demographic spectrum (Pay-for-service hospital catering to middle income populace from India and a free-care public hospital catering to lower income groups from Nepal). We will recruit 720 vegetarian, pregnant women from the antenatal clinics of the Indian and Nepalese centres at their first antenatal visit. Elderly primi mothers, taking B12 supplementation, multiple gestations, chronic medical conditions, anticipating moving out of the city, treated for infertility or with known psychological illnesses will be excluded. In Stage 1, recruited mothers will be randomized into 2 equal groups (360 each). Group 1-Daily 250 μg Vitamin B12 supplementation. Group 2-Daily 50 μg Vitamin B12 supplementation. B-12 will be started in 1st trimester and continue up to 6 months post-partum. In Stage 2, the birth and post-delivery course of the new-born will be monitored and documented for any morbidity. At 9 months, the neurodevelopmental, complementary feeding and home environment will be assessed and infant B12 status will be determined.

The two groups will be compared for the primary (neurodevelopment) and secondary outcomes (biochemical parameters in mother and infant). The results of this study will be used to generate scientific evidence on whether B-12 should be supplemented in vegetarian pregnant women with a view to preventing B-12 deficiency and its neurodevelopmental consequences in the infant.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–35 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Sitaram Bhartia Institute of Science and Research, New Delhi, National Capital Territory of Delhi, India

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • <12 weeks gestation

Vegetarian mothers

Exclusion criteria

  • Mothers already on B12 supplementation
  • Women with multiple gestation, those diagnosed with chronic medical conditions (diabetes mellitus, hypertension, heart disease, neurological disease or thyroid disease), and those who tested positive for hepatitis B, HIV or syphilis (associated with prematurity, IUGR and other neonatal morbidities which could influence neurodevelopment)
  • Women who anticipate moving out of the city before/ after delivery
  • Women treated for infertility
  • Women with known psychological illnesses including depression

Treatment and study plan

Vit B12

Drug

Vitamin B12 250mcg

Primary outcomes

  1. Infant neurodevelopment

    Time frame: 9 Month of infant age

    Developmental Assessment Scale for Indian Infant (modified Bayleys scale) measured as average of motor and mental scores

Secondary outcomes

  1. Biochemical B12 status of mother

    Time frame: At recruitment

    Change in B12 status of mother between first and third trimester

  2. Biochemical B12 status of infant

    Time frame: 9 months of infant age

    Biochemical B12 status of infant at nine months postpartum

Other outcomes

  1. Mean Haemoglobin of infants

    Time frame: 9 months of infant age

    Haemoglobin of infants in grams per deciliter

  2. Infant weight

    Time frame: 9 months of infant age

    Infant weight in kilograms

  3. Infant length

    Time frame: 9 months of infant age

    Infant Length in cms

  4. Infant head circumference

    Time frame: 9 months of infant age

    Infant Head circumference in cms

Sponsors and collaborators

Lead sponsor

Sitaram Bhartia Institute of Science and Research

Other

Collaborators

  • Paropakar Matenity and Women's Hospital, Kathmandu, Nepal
  • Public Health Foundation of India
  • University College, London

Registry information

Acronym: MATCOBIND

Important dates

Study start
2018
Primary completion
2022
Study completion
2022
First posted
Sep 10, 2019
Registry last updated
Oct 26, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.